Home
Clinical Resources Search
PQI: Cabazitaxel (Jevtana®) for Patients with Metastatic Castration-Resistant Prostate Cancer

Cabazitaxel (Jevtana®) for Patients with Metastatic Castration-Resistant Prostate Cancer

About this PQI

Cabazitaxel is indicated for treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with a docetaxel-containing treatment regimen in combination with prednisone. The purpose of this PQI is to provide guidance for initiating cabazitaxel.

More About This PQI

PQI in Action Articles:

Cabazitaxel_Jevtana_MCRPC pdf 2.9MB

PQI in Action Articles:

Cabazitaxel_Jevtana_MCRPC-2 pdf 1.31MB

How to Use a Positive Quality Intervention (PQI)

Essentially, it’s a tool to improve patient care by sharing best practices in oncology care. Consider this standardized, peer-review clinical guidance to oncology healthcare teams, enabling you and your team to consistently deliver high-quality care to your patients.

Find a PQI

Find Similar Resources

All Resources

PQI PQI in Action PQI Podcast Toolkit Treatment Support Kit Video Neuropathy Prostate Cancer Cabazitaxel Jevtana

PQI

Frequently Searched

Supported by

Cabazitaxel (Jevtana®) for Patients with Metastatic Castration-Resistant Prostate Cancer

About this PQI

More About This PQI

PQI in Action Articles:

PQI in Action Articles:

How to Use a Positive Quality Intervention (PQI)

Find Similar Resources

PQI: Eflapegrastim-xnst (Rolvedon) for Chemotherapy-Induced Neutropenia

PQI: Revumenib (Revuforj) for the Management of Acute Leukemia

PQI: Talectrectinib (Ibtrozi) for the Management of ROS1+ Advanced NSCLC

PQI: Zanidatamab-hrii (Ziihera) for the Management of Biliary Tract Cancer

PQI in Action: Abiraterone acetate (Yonsa®) Patient Selection and Management

PQI in Action: Enfortumab Vedotin-ejfv (Padcev®) and Pembrolizumab (Keytruda®) Management for Advanced or Metastatic Urothelial Carcinoma

PQI in Action: Fruquintinib (Fruzaqla®)

PQI in Action: Management of Tucatinib (Tukysa®) and Trastuzumab in HER2-Positive Metastatic Colorectal Cancer – 2

S9 E5: Global Health, Cancer Survivorship, and Advancing Equity

S9 E4: Advancing Pharmacogenomics in Oncology

S9 E3: Firefighter Health & Cancer Prevention

S9 E2: Love Languages in Cancer Care

Readiness Tracker

Treatment Support Kit: Elranatamab

Treatment Support Kit: Mirdametinib

Treatment Support Kit: Abemaciclib

Treatment Support Kit: Temozolomide

Video: Akynzeo® (Ready-to-Use Vial): A Step-by-Step Video Guide

Video: BRUKINSA® (Zanubrutinib) for Treatment of Relapsed or Refractory Marginal Zone Lymphoma

Video: Ibrutinib-Related Cardiac Toxicities: Management & Dose Modifications

Video: Neratinib for Extended Adjuvent Treatment of Adult Patients with Early-Stage HER2-Positive Breast Cancer (MIP)

PQI: Chemotherapy Induced Peripheral Neuropathy

PQI: Brentuximab Vedotin (Adcetris®) Neuropathy and Neutropenia Management

PQI in Action: Abiraterone acetate (Yonsa®) Patient Selection and Management

PQI: Use of Rucaparib (Rubraca®) and Indications

PQI: Talazoparib (Talzenna®) and Enzalutamide (Xtandi®) in HRR Gene-Mutated Metastatic Castration-Resistant Prostate Cancer

PQI: Radium Ra 223 Dichloride (Xofigo®) Management

PQI in Action: Cabazitaxel (Jevtana®) for Patients with Metastatic Castration Resistant Prostate Cancer – 2

PQI in Action: Cabazitaxel (Jevtana®) for Patients with Metastatic Castration Resistant Prostate Cancer – 1

PQI in Action: Cabazitaxel (Jevtana®) for Patients with Metastatic Castration Resistant Prostate Cancer – 2

PQI in Action: Cabazitaxel (Jevtana®) for Patients with Metastatic Castration Resistant Prostate Cancer – 1

S9 E5: Global Health, Cancer Survivorship, and Advancing Equity

PQI: Eflapegrastim-xnst (Rolvedon) for Chemotherapy-Induced Neutropenia

S9 E4: Advancing Pharmacogenomics in Oncology

S9 E3: Firefighter Health & Cancer Prevention